Trovafloxacin
Trovafloxacin is a broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death. It demonstrated excellent activity against gram-positive, gram-negative, and anaerobic organisms. However, it was restricted to hospital use only due to severe hepatotoxicity, including cases of acute liver failure.
Moleküler Ağırlık
416,4000 g/mol
LogP
0,30
TPSA
99,80 Ų
Lipinski RO5
Geçer
Etki Mekanizması
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
2D Yapı
Cite this structure
Embed this structure
SMILES
N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12
InChI
InChI=1S/C20H15F3N4O3/c21-8-1-2-15(13(22)3-8)27-7-12(20(29)30)17(28)9-4-14(23)19(25-18(9)27)26-5-10-11(6-26)16(10)24/h1-4,7,10-11,16H,5-6,24H2,(H,29,30)/t10-,11+,16+
Molecular Formula
C20H15F3N4O3
HBD / HBA
2 / 10
Döndürülebilir Bağlar
3
Ağır Atomlar
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Trovafloxacin is a broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death. It demonstrated excellent activity against gram-positive, gram-negative, and anaerobic organisms. However, it was restricted to hospital use only due to severe hepatotoxicity, including cases of acute liver failure.
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Yes, Trovafloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL428. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 62959. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trovafloxacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trovafloxacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trovafloxacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trovafloxacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trovafloxacin"></drugfyi-drug>